Schering Entering Radiopharmaceuticals Market Via $128 Mil. Diatide Deal
This article was originally published in The Gray Sheet
Schering AG is looking to accelerate its expansion into the worldwide radiopharmaceuticals market through the acquisition of Diatide. The $128 mil. cash deal was announced Sept. 20.
You may also be interested in...
Diatide says that a $2 mil. milestone payment from marketing partner Nycomed Amersham triggered by FDA's Aug. 3 approval of NeoTect will be used in part to bolster its own marketing efforts for the lung cancer imaging agent.
The clinical utility of a negative test result in the imaging of venous thrombosis will be examined in a post-approval study of Diatide's AcuTect. The apcitide technetium Tc 99m kit was approved by FDA Sept. 14.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.